<DOC>
	<DOCNO>NCT02443506</DOCNO>
	<brief_summary>This study evaluate safety AMG 623 subject systemic lupus erythematosus . The study consist 21 day screen period follow administration investigational product 70 day follow period .</brief_summary>
	<brief_title>A Study Examine Safety , Pharmacokinetics Pharmacodynamics Single Dose AMG 623 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Men woman , age 18 55 Diagnosis SLE Have disease duration least 1 year , diagnose physician Have disorder ( include psychiatric ) , condition clinically significant disease ( diagnosis SLE ) would interfere study evaluation , completion and/or procedure per investigator 's discretion Have active vasculitis , active CNS lupus require therapy , active acute renal disease , uncontrolled hypertension , uncontrolled diabetes active systemic infection Have sign symptom viral bacterial infection within 30 day enrollment Have receive daily dose great 10 mg prednisone ( equivalent ) prior 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>